Generex's Net Loss Widens On Interest Expense

Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.

On June 9, 2009, Generex Biotechnology(GNBT Quote) reported that its Q3 FY09 net loss widened on interest expense and the repricing costs of warrants costs issued in connection with convertible debentures, partially offset by a decrease in expenses. Net loss increased to $11.35 million or $0.08 per share from $10.17 million or $0.09 per share a year ago.

Revenue surged to $45,251 from $1,530 in Q3 FY08, reflecting the sales of over-the-counter products and maximum sales from Glucose RapidSpray product. The revenues exclude the amount of deferred sales made to its customers. ...